Ahmed S, Johnson CS, Rueger RM, Trump DL. Calcitriol (1,25 dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. J Urol. 168(2):756-761, 2002

Bandyopadhyay A, Zhu Y, Malik SN, Kreisberg J, Brattain MG, Sprague EA, Luo J, Lopez-Casillas F, Sun L-Z. Extracellular domain of TGF b type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 21:3541-3551, 2002

Belitsky JM, Leslie SJ, Arora PS, Beerman TA, Dervan PB. Cellular Uptake of N-Methylpyrrole/N-Methylimidazole Polyamide-Dye Conjugates. Bioorg. & Med. Chem. 10:23313-3318, 2002

Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL. Antiproliferative effects of 1 alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 143:2508-2514, 2002

Carroll PR, Kantoff PW, Balk SP, Brown MA, D¡¯amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 60:1-6, 2002

Christopher SA, Diegelman P, Porter CW, Kruger WD. Methylthioadenosine phosphorylase, a gene frequently co-deleted with p16cdkN2a/ARF, acts as a tumor suppressor in a breast cancer cell line. Cancer Res. 63(22):6639-6644, 2002

Chu J, Dolnick BJ. Natural antisense (rTSa) RNA induces site-specific cleavage of thymidylate synthase mRNA. Biochemica et Biophysica Acta-Molecular Basis of Disease 1587:183-193, 2002

DeMiguel F, Lee SO, Lou W, Xiao X, Pflug BR, Nelson JB, Gao AC. Stat 3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. Prostate 52:123-129, 2002

Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao AC. Stat3 activation in prostatic carcinomas. Prostate 51:241-246, 2002

Dimitroff CJ, Bernacki RJ, Sakstein R. Glycoslylation-dependent inhibition of cutaneous lymplocyte-associated antigen expression: Implications in modulating lympocyte migration to skin. Blood: On Line September 5, 2002 DOI 10.1182

Dziegielewski J, Beerman TA. Cellular Responses to the DNA Strand-scission Enediyne C-1027 Can Be Independent of ATM, ATR and DNA-PK kinases. J. Biol. Chem. 277:20549-20554, 2002

Evans RL, Poe BS, Goodrich DW. Nuclear localization is required for induction of apoptotic cell death by the Rb-associated p84N5 death by the Rb-associated p84N5 death domain protein. Oncogene, 21(30):4691-4695, 2002

Fakih M, Johnson CS, Trump DL. Glucocorticoids and the treatment of prostate cancer: a review of preclinical and clinical efficacy data. Urology 60:553-516, 2002

Ferbeyre G, de Stanchina E, Lin AW, Querido E, McCurrach M, Hannon G, Lowe SW. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol.Cell.Biol. 22(10):3497-3508, 2002

Foster BA, Evangelou A, Gingrich JR, Kaplan PJ, DeMayo F, Greenberg NM. Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. Differentiation 70(9-10):624-632, 2002

Gangjee A, Dubash NP, Zeng Y, McGuire JJ. Recent advances in the chemistry and biology of folylpoly-g-glutamate synthetase substrates and inhibitors (Invited review). Curr. Medicinal Chem. ?Anticancer Agents 2:331-335, 2002

Gangjee A, Yang J, McGuire JJ, Kisliuk RL. Effect of bridge truncation of classical 2,4-diamino-5-substituted furo[2,3-d]pyrimidine and 2-amino-4-oxo-6-substituted pyrrolo[2,3-d]pyrimidine on antifolate activity. In: S. Milstein, G. Kapatos, R. A. Levine, and B. Shane (eds.), Chemistry and Biology of Pteridines and Folates (Proc. 12th International Symposium), pp. 445-450. Boston: Kluwer Academic Publishers, 2002

Gangjee A, Zeng Y, McGuire JJ, Kisliuk RL. Synthesis of classical and nonclassical, partially restricted, linear, tricyclic 5-deaza antifolates. J.Med.Chem. 45(23):5173-5181, 2002

Gangjee A, Zeng Y, McGuire JJ, Kisliuk RL, Chu E. Synthesis of N-[4-[(2-amino-6-methyl-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidine-5-yl)methyl]-benzoyl]-L-glutamic acid as an antifolate. In: S. Milstein, G. Kapatos, R. A. Levine, and B. Shane (eds.), Chemistry and Biology of Pteridines and Folates (Proc. 12th International Symposium), pp. 439-443. Boston: Kluwer Academic Publishers, 2002

Gangjee A, Zeng Y, McGuire JJ, Kisliuk RL. Synthesis of N-[4-[1-ethyl-2-(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)ethyl]-benzoyl]-L-glutamic acid as an antifolate. J. Med. Chem. 45:1942-1948, 2002

Gupta AK, Alberico RA, Litwin A, Kanter P, Grossman ZD. Gadopentetate dimeglumine is potentially an alternative contrast agent for three-dimensional computed tomography angiography with multidetector-row helical scanning. J. Comput. Assist. Tomogr. 26(6):869-874, 2002

Hapke G, Yin MB, Wu J, Frank C, Rustum YM. Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38. Int. J. Oncol. 21(5):1059-1066, 2002

Hershberger PA, McGuire T F, Yu W-D, Zuhowski EG, Egorin MJ, Trump DL, Johnson CS. Cisplatin potentiates 1,2-dihydroxyvitamin D3-induced apoptosis. Mol Cancer Ther. 1:821-829, 2002.

Huss WJ, Barrios RJ, Foster BA, Greenberg NM. Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. The Prostate 54:1-9, 2002

Ip C, Dong Y, Ip MM, Banni S, Carta G, Angioni E, Murru E, Spada S, Melis MP, Saebo A. Conjugated linoleic acid isomers and mammary cancer prevention, Nutr.Cancer 43(1):52-58, 2002

Johnson CS, Hershberger PA, Bernardi RJ, McGuire TF and Trump DL. Vitamin D receptor: A potential target for intervention. Urology 9:36-41, 2002

Johnson CS, Hershberger PA, Trump DL. Vitamin D-related therapies in prostate cancer. Cancer Metast. Rev. 21:147-158, 2002

Leontieva OV, Preobrazhenskaya MN and Bernacki RJ. Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin 14-o-hemiadpate. Invest. New Drugs 20:35-49, 2002

Liboska R, Zyka D, Bobek M. Synthesis of primary thioamides from nitriles and hydrogen sulfide catalyzed by anion exchange resin. Synthesis No. 12, 1649-1651, 2002

Logan TF, Jadali F, Egorin MJ, Mintun M, Sashin D,Gooding WE, Choi Y, Bishop H, Trump DL, Gardner D, Kirkwood J, Vlock D, Johnson C. Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial.Cancer Chemother Pharmacol. 50(6):433-444, 2002

Malik SN, Brattain MG, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, Kreisberg JI. Immunohistochemical demonstration of phospho AKT in high Gleason grade prostate cancer. Clin. Cancer Res 8:1168-1171, 2002

Marasco CJ Jr, Kramer DL, Miller J, Porter CW, Bacchi CJ, Rattendi D, Kucera L, Iyer N, Bernacki R, Pera P, Sufrin JR. Synthesis and evaluation of analogues of 5?([Z)-4-amino-2-butenyl]methylamino)-5?deoxyadenosine as inhibitors of tumor cell growth, trypanosomal growth, and HIV-1 infectivity. J. Med. Chem. 45(23):5112-5122, 2002

Matin K, Egorin MJ, Ballesteros MF, Smith DC, Lembersky B, Day RS, Johnson CS, Trump DL. Phase I and Pharmacokinetic Study of Vinblastine and High Dose Megestrol Acetate. Cancer Chemother Pharmacol. 50(3):179-185, 2002

Masso-Welch PA, Zangani D, Ip C, Vaughan MM, Shoemaker S, Ramirez RA, Ip MM. Inhibition of antiogenesis by the chemopreventive agent conjugated linoleic acid. Cancer Research 62(15):4384-4389, 2002

Mihich E, Feunteun J, Friend S, Meeting report: Thirteenth Annual Pezcoller Symposium: Focusing Analytical Tools on Complexity in Cancer, Rovereto, Italy, May 31, - June 2, 2001. Cancer Research, 62(13):3882-3887, 2002

Min SH, Simmen RCM, Alhonen L, Halmekyto M, Porter CW, Jänne J, Simmen FA. Altered levels of growth-related and novel gene transcripts in reproductive and other tissues of female mice overexpression spermidine/spermine N1-acetyltransferase (SSAT). J. Biol. Chem. 277(5):3647-3657, 2002

Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS, Trump DL. Pharmacokinetics of high dose calcitriol: results obtained during a phase one trial of calcitriol and paclitaxel. Cancer Pharm Therap. 72(6):648-659, 2002

Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutics agents on patients?colon tumors rown in SCID mice. Cancer Res. 62(20):5800-5806, 2002

Nayak BK, Das GM. Stabilization of p53 and transactivation of its target genes in response to replication blockade. Oncogene 21(47):7226-7229, 2002

Ni Z, Lou W, Lee SO, Shir R, DeMiguel F, Grandis JR and Gao AC. Selective activation of members of the signal tranducers and activators of transcription family in prostate carcinoma. J. Urol. 167:1859-1862, 2002

Ojima I, Geng X, Lin S, Pera P, Bernacki RJ. Design, synthesis and biological activity of novel C2-C3’N-linked macrocyclic taxoids. Bioorg. Med. Chem. Lett. 12(3):349-352, 2002

Sawhney RJ. Expression and regulation of sparc, fibronectin, and collagen IV by dexamethasone in lens epithelial cells. Cell Biol. Internatl., 26(11)971-983, 2002

Sawhney RJ, Zhou G-HK, Humphrey LE, Ghosh P, Kreisberg JI, Brattain MG. Differences in sensitivity of biological functions mediated by epidermal growth factor receptor activation with respect to endogenous and exogenous ligands. J. Biol. Chem. 277(1):75-86, 2002

Siu LL, Rowinsky EK, Weiss GR, Hammond L, Kraynak M, Moczygemba J, Demoor C, Choi L, Linnartz R, Barbet NC, Capdeville R, Von Hoff DD, Porter CW, Eckhardt SG. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily schedule to patients with solid tumors. Clin. Cancer Res. 8:2157-2166, 2002

Spengler ML, Kuropatwinski K, Black AR, Azizkhan-Clifford J. J.SUMO-1 modification of human cytomegalovirus IE1/IE72. Virol. 76(6):2990-2996, 2002

Venkateswarlu S, Dawson DM, St. Clair P, Gupta A, Willson JK, Brattain MG. Autocrine heregulin generates growth factor indepenence and blocks apoptosis in colon cancer cells. Oncogene 21:78-86, 2002

Vujcic S., Diegelman P., Bacchi CJ, Kramer DL and Porter CW. Identification and characterization of a novel flavin-containing spermine oxidase of mammalian cell origin. Biochem. J. 367(3):665-675, 2002

Wang M, Dziegielewski J, Chiang AY, Dervan PB, Beerman TA. Cell-free and cellular activities of a DNA sequence selective hairpin polyamide-CBI conjugate. J. Biol. Chem. 277(45):42431-42437, 2002

Wang D, Patil S, Li W, Humphrey LE, Brattain MG, Howell G. Activation of the TGFa autocrine loop is downstream of IGF-I receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells. Oncogene 21:2785-2796, 2002

White CM, Satz AL, Gawron L, Bruice TC, Beerman TA. Inhibiting transcription factor/DNA complexes using fluorescent microgonotropens (FMGTs). Biochim. Biophys. Acta, 1574: 100-108, 2002

Wu J, Yin MB, Hapke G, Toth K, Rustum YM. Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin. Mol Pharmacol. 61(4):742-748, 2002

Yin S, Bailiang W, Xie K, Goodrich DW. Adenovirus-Mediated N5 Gene Therapy Inhibits Tumor Growth and Metastasis in Mouse Models of Human Pancreatic Carcinoma, Cancer Gene Therapy 9(8):665-672, 2002

Yin MB, Hapke G, Wu J, Azrak RG, Frank C, Wrzosek C and Rustum YM. Chk 1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topooisomerase I poison BNP1350. Biochem. Biophys. Res. Commun. 295:435-444, 2002

Zhou M, Gu L, Li F, Zhu Y, Woods W, Findley HW. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. The Journal of Pharmacology and Experimental Therapeutics, 303(1): 124-131, 2002